| Apixaban |
| The use of apixaban was considered appropriate if |
-
(1)
The dose was 5 mg BID for nonvalvular AF or 2.5 mg BID if two of the following were present: age 80 years or older, weight 60 kg or less, serum creatinine (SCr) 1.5 mg/dl or greater4
-
(2)
The dose was 2.5 mg BID for VTE prevention post-hip or knee replacement
-
(3)
The dose was 10 mg BID for one week followed by 5 mg BID for 6 months for patients diagnosed with DVT or PE after August 21st, 2014
-
(4)
The patient was not receiving a strong inducer of both CYP3A4 and P-glycoprotein
-
(5)
Dose reduction with concomitant use of strong inhibitors of both CYP3A4 and P-glycoprotein
-
(6)
Apixaban was discontinued 24 to 48 h in patients with CrCl > 15 ml/min or 36–48 h in patients with CrCl < 15 ml/min prior to a procedure
-
(7)
The INR was <2 if switched from warfarin to apixaban or apixaban was discontinued once an INR of 2–3 was achieved in those being converted from apixaban to warfarin or apixaban was discontinued once parenteral anticoagulation was initiated
|
|
|
| Dabigatran |
| The use of Dabigatran was considered appropriate if |
-
(1)
The dose was 150 mg BID for nonvalvular AF or 75 mg BID if the CrCl was 15–30 ml/min2
-
(2)
The dose was 150 mg BID for treatment of DVT or PE after April 7th, 2014
-
(3)
The patient was not on any strong inducers of both CYP3A4 and P-glycoprotein
-
(4)
Dose reduction was considered with concomitant use of strong inhibitors of both CYP3A4 and P-glycoprotein
-
(5)
Dabigatran was discontinued with CrCl < 15 ml/min in AF or <30 ml/min in the treatment of VTE
-
(6)
Dabigatran was discontinued 24–48 h with CrCl > 50 ml/min or 48–96 h with CrCl 30–50 ml/min prior to a procedure
-
(7)
The INR was <2 if the patient was switched from warfarin to dabigatran or dabigatran was discontinued once an INR of 2–3 was achieved in those being converted from dabigatran to warfarin or dabigatran was discontinued once parenteral anticoagulation was initiated
|
|
|
| Rivaroxaban |
| The use of rivaroxaban was considered appropriate if |
-
(1)
The dose was 20 mg daily with nonvalvular AF, or 15 mg daily with a CrCl of 15–50 ml/min3
-
(2)
The dose was 10 mg daily for VTE prevention post-hip or knee replacement
-
(3)
The dose was 15 mg BID for three weeks followed by 20 mg daily for the treatment of DVT or PE
-
(4)
The patient was not on any strong inducers or inhibitors of both CYP3A4 and P-glycoprotein
-
(5)
Rivaroxaban was discontinued in patients with CrCl < 15 ml/min in AF and <30 ml/min in VTE prevention or treatment
-
(6)
Rivaroxaban was discontinued 24–48 h with CrCl > 15 ml/min or 36–48 h with CrCl < 15 ml/min prior to a procedure
-
(7)
The INR was <3 if the patient was switched from warfarin to rivaroxaban or rivaroxaban was discontinued once an INR of 2–3 was achieved in those being converted from rivaroxaban to warfarin or rivaroxaban was discontinued once parenteral anticoagulation was initiated
|
